Babcock University Research Portal

The use of magnesium sulphate (MgSO4) for seizure prophylaxis: clinical correlates in a Nigerian tertiary hospital

Authors: IMARALU John , OLALEYE Atinuke , Badejoko O, Loto M, Ogunniyi Solomon O

Publication Type: Journal article

Journal: International Journal Of Medicine And Biomedical Research

ISSN Number:

Downloads

Views

Abstract

Background: Magnesium sulphate use in the prevention of seizures resulting from preeclampsia
and eclampsia is widely accepted. However, several protocols exist worldwide. Aim: To
determine serum magnesium levels and associated clinical outcomes in severe pre-eclamptic and
eclamptic women treated with magnesium sulphate. Methods: Women, 28-41weeks pregnant or in
the puerperium with severe pre-eclampsia or eclampsia, participated in this cross sectional study
and their serum magnesium levels were measured using the Atomic Absorption Spectrophotometer
(AAS) machine. All participants received the standard Pritchard regimen, including monitoring.
Results: Seventy five patients participated in the study. They were mostly overweight (mean BMI
26.38 ± 3.40kg/m2). Mean pre-treatment serum magnesium level was 1.96 ± 0.29 mg/dL;
eclamptics had significantly lower levels (p<0> attained was 5.41 ± 0.58 mg/dL. No evidence of magnesium toxicity was observed. Therapeutic
range of serum magnesium was required to prevent seizures, and was attained ?4-hours after
loading dose in most of the eclamptics (74%). All convulsions occurred in the interval between the
loading dose and the first maintenance dose; eclamptics had greater risk of convulsing while on
treatment (RR=11.56, 95%CI= 0.62-216.36, P=0.049). Conclusion: Low serum magnesium level
before or during treatment with magnesium sulphate is a risk factor for convulsion in OAUTHC. The
Pritchard regimen has a low risk for toxicity thus administration of magnesium sulphate at
peripheral centres before referral may be beneficial in preventing repeat convulsions. Modifications
involving additions to the loading dose in eclamptics and fewer number of maintenance doses may
be beneficial.

Access to Documents

External Link
Download
Digital Object Identifier

Keywords

IMARALU,J. OLALEYE,A. Badejoko,O.O Loto,O.M Ogunniyi,S.O . (0000). The use of magnesium sulphate (MgSO4) for seizure prophylaxis: clinical correlates in a Nigerian tertiary hospital, 4 (), 72-72.

IMARALU,J. OLALEYE,A. Badejoko,O.O Loto,O.M Ogunniyi,S.O . "The use of magnesium sulphate (MgSO4) for seizure prophylaxis: clinical correlates in a Nigerian tertiary hospital" 4, no (), (0000): 72-72.

IMARALU,J. and OLALEYE,A. and Badejoko,O.O and Loto,O.M and Ogunniyi,S.O and . (0000). The use of magnesium sulphate (MgSO4) for seizure prophylaxis: clinical correlates in a Nigerian tertiary hospital, 4 (), pp72-72.

IMARALUJ, OLALEYEA, BadejokoOO, LotoOM, OgunniyiSO, . The use of magnesium sulphate (MgSO4) for seizure prophylaxis: clinical correlates in a Nigerian tertiary hospital. 0000, 4 ():72-72.

IMARALU,John , OLALEYE,Atinuke , Badejoko,Olusegun O, Loto,Olabisi M, and Ogunniyi,Solomon O . "The use of magnesium sulphate (MgSO4) for seizure prophylaxis: clinical correlates in a Nigerian tertiary hospital", 4 . (0000) : 72-72.

I.John O.Atinuke B.Olusegun O L.Olabisi M & O.Solomon O , "The use of magnesium sulphate (MgSO4) for seizure prophylaxis: clinical correlates in a Nigerian tertiary hospital" vol.4, no., pp. 72-72, 0000.

Access to Documents

Keywords

About Us

Admissions

Contact Us

Policies

ALUMNI

STUDENT POPULATION